The selected Vyvanse label covers lisdexamfetamine for adult ADHD and moderate to severe binge eating disorder in adults, not weight loss. Its capsules and chewable tablets share an active ingredient, but important safety findings depend on the condition studied. The label explains possible benefits and risks without predicting your experience. FDA labeling, section 1 and Medication Guide.
Reading about a prescription can raise several different concerns: what it treats, whether an appetite change means it is working, or why another medicine or a planned scan matters. This article examines the selected Takeda Vyvanse oral capsule and chewable-tablet record, effective April 30, 2026, with a Medication Guide revised April 2026. Those identify the source, not this article's publication date or proof that the record remains the latest label. The discussion does not extend every detail to every lisdexamfetamine product, establish a diagnosis, or provide directions for using or changing a prescription.
What adult uses does this Vyvanse label cover?
The label covers adult ADHD and moderate to severe binge eating disorder, two distinct treatment purposes. For context, MVBH explains product-specific Medication Guide information separately from the Vyvanse and Adderall comparison for adult ADHD. Neither resource makes a prescription a diagnostic test.
For ADHD, the Medication Guide describes possible improvement in attention and reductions in impulsiveness and hyperactivity. For adults with moderate to severe binge eating disorder, it describes a possible reduction in binge eating days. These are different descriptions of benefit. The binge eating indication does not establish treatment for ordinary overeating, bulimia nervosa, or every eating disorder. FDA labeling, section 1 and Medication Guide.
The weight-loss boundary deserves particular attention because appetite reduction and weight loss also appear in the adverse-reaction information. An adverse reaction describes an unwanted effect observed during treatment, not an approved reason to use the medicine. The selected label explicitly excludes weight loss and states that safety and effectiveness for obesity treatment have not been established.
That distinction remains important even when weight changes feel noticeable or welcome. Weight change alone does not demonstrate improvement in ADHD or fewer binge eating days. Likewise, knowing that someone has a Vyvanse prescription does not reveal their diagnosis or establish why it was prescribed.
What do the two forms and the prodrug description mean?
This record covers oral capsules and chewable tablets containing lisdexamfetamine dimesylate. MVBH's existing explanation of prodrugs and release systems provides background, while matching information to the exact product helps keep formulation details in context. The two forms are not simply stronger and weaker versions.
Their inactive ingredients differ. The capsule shells contain gelatin, titanium dioxide, and specified coloring ingredients; the chewable-tablet list includes mannitol, sucralose, guar gum, and artificial strawberry flavor. These examples illustrate different formulations, not a complete ingredient list or a way to clear a product for personal use. Shared active ingredients do not establish identical tolerability or substitution instructions. FDA labeling, section 11 and Medication Guide ingredients.
Lisdexamfetamine is a prodrug of dextroamphetamine, meaning it is converted into that active substance. However, section 12.1 explicitly says its exact therapeutic action in both ADHD and binge eating disorder is unknown. The prodrug description therefore does not explain every treatment effect or guarantee faster benefit, greater safety, or lower addiction risk.
How do the adult ADHD and binge eating safety findings differ?
The label reports separate adult study populations, so their findings are not interchangeable personal forecasts. Beyond MVBH's broader stimulant side-effect comparison, its guide to interpreting serious-risk information explains why a reported possibility is not a prediction. Here, the study context matters as much as the reaction's name.
The following comparison uses the adult ADHD findings in Table 3 and the adult binge eating disorder findings in Table 4, rather than treating the combined child-and-adult ADHD summary as adult-only evidence. FDA labeling, section 6.1.
| Evidence feature | Adult ADHD study | Adult binge eating disorder studies |
|---|---|---|
| Study context | A four-week controlled trial | Two twelve-week placebo-controlled trials |
| Prominent reactions | Decreased appetite, insomnia, and dry mouth; diarrhea, nausea, and anxiety also reported | Dry mouth, insomnia, decreased appetite, increased heart rate, constipation, jitteriness, and anxiety |
| Participant restrictions | Adult ADHD population; not the same study group as the binge eating trials | Cardiovascular risk factors other than obesity and smoking were excluded |
| Interpretation limit | Cannot forecast an individual's reactions or establish long-term experience | Cannot establish safety for people excluded from these studies |
Insomnia means difficulty sleeping; dry mouth and gastrointestinal effects can affect everyday comfort. Jitteriness describes feeling physically unsettled, while anxiety is reported separately. Increased heart rate appears in both adult tables, but it is among the most common reactions identified for the binge eating population. The findings do not make all these effects equally common in both groups.
The adult ADHD findings also report erectile dysfunction and reduced libido. These observations deserve recognition without assuming that any individual's sexual-function change has one cause. Separately, section 6.2 lists voluntary postmarketing reports. Because their population size is uncertain, those reports cannot reliably establish frequency or always establish causation.
Which serious lisdexamfetamine warnings need attention?
Serious warnings concern potential harm, not just how uncomfortable a common reaction feels. MVBH's resources on reading warnings in product context and stimulant safety concerns provide background. The selected label distinguishes several risks that require different kinds of attention.
The boxed warning describes a high potential for abuse and misuse, which can lead to addiction, overdose, and death. The Medication Guide also states that physical dependence can occur after prolonged use even when taken as directed. Physical dependence is not, by itself, proof of misuse or addiction. FDA boxed warning and Medication Guide.
- Heart and circulation: The label warns about serious cardiac disease, increased blood pressure and pulse, and finger or toe circulation problems. Digital changes can include numbness, pain, coldness, color changes, or wounds.
- Psychiatric effects: Existing psychotic or bipolar symptoms may worsen, and new hallucinations, delusional thinking, or manic symptoms can occur without a previous history.
- Serotonin syndrome: This potentially life-threatening reaction can involve changes in mental state, high temperature, fast heartbeat, muscle stiffness or twitching, and gastrointestinal symptoms.
- Tics: New or worsening repeated movements or sounds, including worsening Tourette's syndrome, are identified in the warnings.
These categories are explanations, not a self-diagnostic checklist. The Medication Guide calls for immediate medical attention for chest pain, shortness of breath, or fainting during treatment. New or worsening psychiatric symptoms require prompt contact with a healthcare professional. Unexplained finger or toe wounds warrant immediate clinician contact, and suspected serotonin syndrome needs urgent medical assessment. FDA labeling, sections 5 and 17 and Medication Guide.
Call 911 for immediate danger or a life-threatening medical emergency. For suicidal thoughts or crisis support, call or text 988. NIMH safety guidance distinguishes these resources from routine treatment. MVBH is not an emergency service.
Why do other medicines and certain brain scans matter?
The label identifies different interaction concerns, plus a specific imaging interference that is not an ordinary drug combination. MVBH's guide to using product-specific risk information offers context, but the relevant details here come from sections 4, 5.7, and 7 of the selected label.
- MAO inhibitors: Their combination with Vyvanse is contraindicated because of the risk of hypertensive crisis, a dangerous blood-pressure emergency. The label includes linezolid and intravenous methylene blue in this concern.
- Serotonergic medicines: SSRIs, SNRIs, triptans, lithium, tramadol, buspirone, and other named products can increase serotonin-syndrome risk. The label also names St. John's wort.
- CYP2D6 inhibitors: CYP2D6 is an enzyme involved in processing medicines. Medicines that inhibit it may increase exposure to dextroamphetamine, the active metabolite. Exposure means how much medicine the body encounters over time. This can also increase serotonin-syndrome risk, through a distinct interaction mechanism.
- Tricyclic antidepressants: The label describes potentially enhanced cardiovascular effects, in addition to their appearance among serotonergic medicines.
These examples explain why interactions cannot be reduced to a generic warning about mixing medicines. They are not a complete list, a safe-combination guide, or instructions for managing a combination. FDA labeling, sections 4, 5.7, and 7.1.
The imaging issue is unusually specific. Section 7.2 identifies possible interference with ioflupane I-123, a radioactive diagnostic agent used to visualize dopamine transporters. Vyvanse may affect the apparent transporter finding in a brain region called the striatum, potentially leading to false-positive diagnostic results. FDA labeling, section 7.2.
This passage is about that imaging procedure, not a general urine-drug-screen claim. It neither proves that a particular scan is false nor gives an individual permission to interrupt medication. The prescribing and imaging professionals must interpret the finding and any procedure-related medication directions.
What special adult safety limits does the label identify?
Pregnancy, lactation, older age, and kidney impairment involve different evidence limits or safety concerns. They cannot be collapsed into one safe-or-unsafe conclusion. MVBH's explanation of the limits of product risk information provides context for reading these distinctions without turning them into personal treatment instructions.
For pregnancy, the available published and postmarketing data are insufficient to determine a drug-associated risk of major birth defects or miscarriage. That uncertainty does not establish safety: the label also warns of potential fetal harm. Animal findings and reports involving amphetamine-dependent mothers cannot be converted into a prediction for an individual pregnancy. FDA labeling, section 8.1.
For lactation, limited reports establish that amphetamine is present in human milk, while long-term neurodevelopmental effects on exposed infants remain unknown. Because of potential serious infant reactions, the label states that breastfeeding is not recommended during Vyvanse treatment. This describes the label's warning, not an individualized feeding or medication recommendation. FDA labeling, section 8.2.
Trials included too few adults aged 65 and older to determine whether their responses differ from younger adults. Other reported experience did not identify response differences, but that does not resolve the trial gap. Severe renal impairment presents a different issue: reduced clearance means the medicine's elimination is slower, creating specific prescribing considerations. FDA labeling, sections 8.5 and 8.6.
These distinctions fit NIMH's broader principle that treatment planning reflects individual needs and medical circumstances under professional guidance. A label informs that work; it does not complete it.
Written by Tim Francis, SUD Content Specialist. This educational article does not diagnose, prescribe, or establish that MVBH provides lisdexamfetamine or related imaging or specialist services.
Frequently asked questions
Does a Vyvanse prescription mean someone has ADHD?
No. The selected label includes both adult ADHD and moderate to severe binge eating disorder in adults. A prescription alone does not establish which condition is being addressed or reveal a person's diagnosis. The labeled uses describe approved treatment purposes, not a way to diagnose someone from their medicine.
Is reduced appetite evidence that binge eating treatment is working?
Reduced appetite is listed as an adverse reaction, whereas the Medication Guide describes possible benefit for binge eating disorder in terms of fewer binge eating days. Those are not interchangeable findings. Appetite reduction or weight change alone does not establish therapeutic benefit, and the selected label does not approve Vyvanse for weight loss.
Do the capsules and chewable tablets have identical ingredients?
They share lisdexamfetamine dimesylate as the active ingredient, but their inactive ingredient lists differ. The selected label describes separate capsule, capsule-shell, and chewable-tablet ingredients. Shared active ingredients do not establish identical personal tolerability, faster benefit, or permission to substitute one form for another.
Does physical dependence prove that a person misused Vyvanse?
No. The Medication Guide states that physical dependence may develop after prolonged use even when the medicine is taken as directed. That statement does not itself establish misuse or addiction. The separate boxed warning still identifies serious abuse, misuse, addiction, overdose, and death risks; neither statement cancels the other.
Does the imaging warning mean every brain scan is unreliable?
No. The selected label identifies possible interference with ioflupane I-123 dopamine-transporter imaging, not every brain scan. It describes the possibility of false-positive diagnostic results, not proof that an individual's result is false. The warning does not supply personal medication-interruption instructions or establish a general urine-drug-screen interference claim.
